121 related articles for article (PubMed ID: 6230516)
1. Phase II evaluation of chlorozotocin in metastatic sarcomas.
Presant CA; Bartolucci AA
Med Pediatr Oncol; 1984; 12(1):25-7. PubMed ID: 6230516
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced soft tissue sarcoma with chlorozotocin: a phase II trial of the EORTC soft tissue and bone sarcoma group.
Mouridsen HT; Bramwell VH; Lacave J; Metz R; Vendrik C; Hild J; McCreanney J; Sylvester R
Cancer Treat Rep; 1981; 65(5-6):509-11. PubMed ID: 6453646
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Amato DA; Borden EC; Shiraki M; Enterline HT; Rosenbaum C; Davis HL; Paul AR; Stevens CM; Lerner HJ
Invest New Drugs; 1985; 3(4):397-401. PubMed ID: 2417985
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of piperazinedione in metastatic sarcoma.
Presant CA; Bartolucci AA
Am J Clin Oncol; 1982 Apr; 5(2):185-7. PubMed ID: 7046413
[TBL] [Abstract][Full Text] [Related]
5. Chlorozotocin: phase II evaluation in patients with advanced sarcomas.
Sordillo PP; Magill GB; Gralla RJ
Cancer Treat Rep; 1981; 65(5-6):513-4. PubMed ID: 6453647
[No Abstract] [Full Text] [Related]
6. Phase II study of chlorozotocin in malignant melanoma: a Southeastern Cancer Study Group report.
Van Amburg AL; Presant CA; Burns D
Cancer Treat Rep; 1982 Jun; 66(6):1431-3. PubMed ID: 6211234
[TBL] [Abstract][Full Text] [Related]
7. Phase I evaluation of chlorozotocin (NSC-178248): weekly schedule.
Moriconi WJ; Taylor S; Slavik M; Belt RJ; Haas CD; Hoogstraten B
Invest New Drugs; 1985; 3(1):57-62. PubMed ID: 3157661
[TBL] [Abstract][Full Text] [Related]
8. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study.
Samson MK; Baker LH; Benjamin RS; Lane M; Plager C
Cancer Treat Rep; 1979; 63(11-12):2027-9. PubMed ID: 575067
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578).
Creech RH; Stanley K; Vogl SE; Ettinger DS; Bonomi PD; Salazar O
Cancer Treat Rep; 1982 Jun; 66(6):1417-9. PubMed ID: 6282460
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.
Talley RW; Samson MK; Brownlee RW; Samhouri AM; Fraile RJ; Baker LH
Eur J Cancer (1965); 1981 Mar; 17(3):337-43. PubMed ID: 6455296
[No Abstract] [Full Text] [Related]
11. Phase II evaluation of PALA in patients with refractory metastatic sarcomas.
Kurzrock R; Yap BS; Plager C; Papdopoulos N; Benjamin RS; Valdivieso M; Bodey GP
Am J Clin Oncol; 1984 Aug; 7(4):305-7. PubMed ID: 6741860
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of chlorozotocin in islet cell carcinoma. A southwest Oncology Group study.
Bukowski RM; McCracken JD; Balcerzak SP; Fabian CJ
Cancer Chemother Pharmacol; 1983; 11(1):48-50. PubMed ID: 6309425
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of chlorozotocin in metastatic malignant melanoma.
Hoth DF; Schein PS; Winokur S; Woolley PV; Robichaud K; Binder RB; Smith FP
Cancer; 1980 Oct; 46(7):1544-7. PubMed ID: 6448088
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
González-Manzano R; Vieitez JM; Tangco E; Fernandez de Alava E; Herranz P; Garcia-Foncillas J
Am J Clin Oncol; 1993 Aug; 16(4):332-7. PubMed ID: 8328412
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
Bramwell VH; Morris D; Ernst DS; Hings I; Blackstein M; Venner PM; Ette EI; Harding MW; Waxman A; Demetri GD
Clin Cancer Res; 2002 Feb; 8(2):383-93. PubMed ID: 11839653
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
[TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
Borden EC; Amato DA; Edmonson JH; Ritch PS; Shiraki M
Cancer; 1990 Sep; 66(5):862-7. PubMed ID: 2201431
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008
[TBL] [Abstract][Full Text] [Related]
19. High-dose cisplatin for metastatic soft tissue sarcoma.
Budd GT; Metch B; Balcerzak SP; Fletcher WS; Baker LH; Mortimer JE
Cancer; 1990 Feb; 65(4):866-9. PubMed ID: 2297655
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of elliptinium in metastatic soft tissue sarcoma.
Somers R; Rouësse J; van Oosterom A; Thomas D
Eur J Cancer Clin Oncol; 1985 May; 21(5):591-3. PubMed ID: 4007025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]